Life Sciences Industry Report - Part 5
Developments in the oncology space in 2024 brought hope to both industry and patients. Certainly, there was – though the term be often used – a paradigm shift in thought processes and in drug discovery and delivery.
In Part 5 of our Life Sciences Industry Report, we turn our attention to the oncological field of research and development, from cancer therapies to cancer care, from clinical trials to the patient’s everyday lived experience.
Last year, over 12 months there was honed a critical focus on the very language of cancer, an awareness of the importance of utilising words sharpened, it finally being understood that easily digestible information avoids patients becoming overwhelmed by complex jargon. Similarly, the very notion of cancer survivorship and ameliorating care options for those of the other side of diagnosis and surgery was more widely discussed.
With market data, including top- performing oncology drugs, and key takeaways from the year, an R&D focus that brings to its core the patient perspective is what became clear last year, and not only in oncology. And that essentially mutually beneficial understanding looks set to deepen in 2025, and beyond, across the breadth of the life sciences.
Delve into all this in Part 5 of pharmaphorum’s inaugural Life Sciences Industry Report 2025. Download Part 5 today.
